MedPlus Health Services has announced the approval of its Q3 2026 financial results and the allotment of 232,061 equity shares under the Employee Stock Option Plan 2021. The board approved the unaudited standalone and consolidated financial results for the quarter ended December 31, 2025. The results reflect the company’s performance and strategic decisions during the financial period. Further details are available on the company’s website.
Q3 2026 Financial Performance
The Board of Directors of MedPlus Health Services has approved the unaudited standalone and consolidated financial results for the quarter ended December 31, 2025. Key highlights from the consolidated results include:
- Total Income: ₹18,243.59 million
- Profit Before Tax: ₹732.87 million
- Net Profit After Tax: ₹577.88 million
These financials reflect the company’s performance during Q3 2026, providing insight into its revenue and profitability.
ESOP Allotment
The board has also approved the allotment of 232,061 equity shares under the MedPlus Employees Stock Option Plan 2021 (‘ESOP,2021’) to eligible employees. Detailed disclosures regarding this allotment, as required under SBEB Regulations, will be provided separately. MedPlus has clarified that the share allotment is not material in nature to the company.
Standalone Financials Overview
Key figures from the standalone financial results include:
- Total Income: ₹2,256.98 million
- Profit Before Tax: ₹218.26 million
- Net Profit After Tax: ₹165.76 million
These results offer a view of the company’s standalone financial health for the same period.
Source: BSE
